NP@ESCu can trigger cuproptosis and enhance immune response by the production of elesclomol and copper, which has been validated in tumor cells and animal models of bladder cancer to show an anti-tumor effect with PD-L1 blockade [173]. This evidence concerns the gene CD274 and neoplasm.